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Abstract 
T-cell infiltration into tumors represents a critical bottleneck for immune-
mediated control of cancer. We previously showed that this bottleneck can be 
overcome by depleting immunosuppressive Foxp3+ regulatory T cells (Tregs), a 
process which can increase frequencies of tumor-infiltrating lymphocytes (TILs) 
through promoting development of specialized portals for lymphocyte entry, namely 
high endothelial venules (HEVs). In this paper, we used a carcinogen-induced tumor 
model, that allows for co-evolution of the tumor microenvironment and the immune 
response, to demonstrate that Treg depletion not only results in widespread disruption 
to HEV networks in lymph nodes (LNs) but activates CD8+ T cells, which then drive 
intratumoral HEV development. Formation of these vessels contrasts with ontogenic 
HEV development in LNs in that the process is dependent on TNF receptor and 
independent of lymphotoxin β receptor-mediated signaling. These intratumoral HEVs 
do not express the chemokine CCL21, revealing a previously undescribed 
intratumoral blood vessel phenotype. We propose a model where Treg depletion 
enables a self-amplifying loop of T-cell activation, which promotes HEV 
development, T-cell infiltration, and ultimately, tumor destruction. The findings point 
to a need to test for HEV development as part of ongoing clinical studies in patients 
with cancer.  
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Introduction 
 Evidence indicates that the extent of T-cell infiltration into tumors is a key 
parameter influencing cancer immunity (1-5). Our previous studies revealed an 
influence of Foxp3+ regulatory T cells (Treg) on the numbers of infiltrating T cells 
(6,7). Specifically, we found that Treg depletion promotes development of high 
endothelial venules (HEVs), whose presence is associated with significantly increased 
numbers of T cells and better control of tumor growth (6). HEVs develop during 
ontogenic secondary lymphoid organ development, which is initiated by interactions 
between lymphotoxin (LT) β receptor (LTβR)-expressing lymphoid tissue organizer 
(LTo) cells and LTα1β2-expressing lymphoid tissue inducer (LTi) cells (8). A role for 
canonical LTi cells in intratumoral HEV neogenesis following Treg depletion was 
excluded in our previous study, indicating that this process is governed by different 
cues than those dictating HEV development in lymph nodes (LNs) (6). 
The current study set out to identify the mechanisms underpinning HEV 
development using a mouse model of carcinogen-induced fibrosarcoma that allows 
for evolving interactions between the immune system and cancer cells during the 
process of transformation. Such reciprocal interactions shape development of the 
tumor microenvironment, the nature of the immune response, and tumor 
immunogenicity (9). A key feature of this carcinogen-induced tumor model is that 
vessels expressing peripheral node addressin (PNAd; the hallmark of HEV), are not 
detected in tumors from Treg-replete mice, indicating that Treg depletion is a 
prerequisite to development of HEV (6). Therefore, the interactions of T and B 
lymphocytes and DCs, which become highly activated following Treg depletion 
(6,10), may be essential for coordinating HEV formation in the tumors described 
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herein. This study reports the findings of experiments designed to test this hypothesis 
and their implications for cancer immunotherapy.  
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Materials and Methods 
Mice 
We are grateful to Professor Rudensky for supplying Foxp3DTR mice and to 
Professor Hammerling for supplying CD11c.DOG mice. Each have been described 
previously (10,11). Foxp3DTR mice express knocked-in human diphtheria toxin 
receptor (DTR) and enhanced green fluorescent protein (EGFP) genes under the 
control of the Foxp3 promoter, allowing specific elimination of Tregs in vivo. These 
mice were backcrossed with C57BL/6 mice for ≥5 generations. CD11c.DOG mice 
express the human DTR together with a fragment of the ovalbumin protein and EGFP 
on a bacterial artificial chromosome under the control of the CD11c promoter, 
allowing efficient elimination of CD11c-expressing cells in vivo. Male CD11c.DOG 
mice were bred with female Foxp3DTR mice. F2 and F3 progeny were genotyped by 
PCR for FoxP3DTR homozygosity (females) or hemizygosity (males) and the presence 
of the CD11cDTR gene. Those with both Foxp3DTR and CD11cDTR genes 
(CD11c.DOG-Foxp3DTR) were used in future experiments. Mice were housed in 
accordance with UK Home Office regulations, isolator-bred, and housed in filter-top 
cages for the duration of experiments. 
Tumor induction and diphtheria toxin administration 
Anesthetized mice (8-15 weeks old) were injected subcutaneously with 400 μg 
of 3-methylcholanthrene (MCA; Sigma-Aldrich) in 100 μl olive oil to induce tumors 
as previously described (12). Mice were monitored for tumor development weekly for 
up to 18 months. Diphtheria toxin (DT; Sigma-Aldrich) in 100 μl PBS was 
administered by intraperitoneal (i.p.) injection (5ng/g body weight to deplete Tregs; 
8ng/g body weight to deplete Tregs and CD11c+ cells) every other day after palpable 
on October 5, 2017. © 2017 American Association for Cancer Research. cancerimmunolres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on September 25, 2017; DOI: 10.1158/2326-6066.CIR-17-0131 
 5 
tumor development. Once tumors became palpable, they were measured using 
calipers every other day (tumor width, tumor height, tumor leg diameter and non-
tumor leg diameter), and tumor growth rate (k, days-1) was calculated using the 
difference between tumor and nontumor leg diameters by the following equation: Y= 
Y0 x exp (k x X). Mice were sacrificed before tumors reached 1.5cm in diameter or if 
tumors caused apparent discomfort (irritation or decreased mobility). 
In vivo treatments 
All treatments were administered by i.p. injection. Depleting CD4– and CD8-
specific antibodies were produced in-house (13). Briefly, hybridomas expressing 
depleting CD4– and CD8-specific antibodies were produced in vitro and antibodies 
were purified on protein-G affinity columns. 100 μg anti-CD4 (clones YTS-191 and 
YTA-3) and/or anti-CD8 (clones YTS-156 and YTS-169) mAbs were administered 
every other day beginning one day prior to DT. Mouse LTβR.Fc (10 mg/kg body 
weight; received from Dr. Grogan or Prof. Ware (14-16)) and Etanercept (5 mg/kg 
body weight; TNFRII.Ig; Enbrel®, Amgen/Wyeth) were administered every other day 
alongside DT. 2 mg anti-mouse TNF mAb (MP6-XT22; produced in-house as 
detailed above) was administered beginning one day before DT, after which 1 mg was 
given every other day. Anti-mouse LT-α mAb (clone S5H3), received from Dr 
Grogan (14), was administered (6 mg/kg body weight) every other day beginning one 
day prior to DT. Mice received 100 μg of agonistic anti-LTβR mAb (clone 4H8), 
received from Professor Ware (17,18) every 3-4 days. 
Dissection of tissues 
Spleen and inguinal LNs were removed, and tumors were resected avoiding muscle, 
other tissues, and the popliteal LN. 
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Flow cytometry 
Spleens and LNs were mashed through a 70 μm cell strainer (BD Biosciences) 
using the back of a syringe plunger. Tumors were mechanically dissociated by dicing 
into small (~1-2mm) pieces using a scalpel and then mashed through a 70 μm cell 
strainer using the back of a syringe plunger. Cell suspensions were resuspended in 
complete RPMI (cRPMI; RPMI [Invitrogen] plus 2 mM L-glutamine, 1 mM sodium 
pyruvate, pen/strep [50 μg/ml], and 10% FCS) and passed through a 70 μm cell 
strainer. Cells were washed with PBS, and red blood cells in tumor and spleen pellets 
were lysed using RBC lysis buffer (Biolegend). Cells were washed with PBS, stained 
using LIVE/DEAD Aqua (Invitrogen), then washed and Fc receptors blocked with 
anti-CD16/32 (clone 93; eBioscience) before staining with surface antibodies (listed 
in Supplementary Table S1).  
For intracellular TNF analysis, cells were stimulated in 24-well plates with 20 
nM PMA (Sigma-Aldrich) and ionomycin (1 μg/ml; Sigma-Aldrich) at 37°C for 4 
hours. After 1 hour, GolgiStop (1μl/ml; BD Biosciences) was added. Cells were 
stained for surface markers and then TNF following fixation/permeabilization 
following the manufacturer’s protocol (Foxp3-staining kit; eBiosciences). Data were 
acquired on a FACS Canto II (BD Biosciences) and analyzed using FlowJo (TreeStar, 
USA). 
Immunohistochemistry 
5 μm neutral buffered-formalin solution (NBFS) fixed, paraffin-embedded 
tumor sections were mounted, and then rehydrated in xylene, descending alcohol 
concentrations, and dH2O. Antigen retrieval was performed in Tris (10 mmol/L), 
EDTA (pH9, 1 mmol/L). Endogenous peroxidase activity was quenched using 1% 
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H2O2/MeOH, and nonspecific binding was blocked with 2.5% normal horse serum 
(VectorLabs). Sections were incubated in rat anti-PNAd (clone MECA-79; 
Biolegend) overnight at 4°C, washed with PBS, and then incubated in anti-Rat 
ImmPRESSTM HRP Polymer Detection solution (VectorLabs). Slides were briefly 
incubated in Vector® chromagen DAB HRP substrate (VectorLabs), rinsed with 
dH2O, and counterstained in haematoxylin. Slides were then dehydrated via an 
ascending alcohol gradient and xylene and mounted in distyrene, plasticizer, xylene 
mountant (DPX; Sigma-Aldrich).  
Paraffin-embedded tumors stained using anti-PNAd were scanned using a 
Zeiss Axio Scan.Z1 slide scanner. HEVs were indicated, including the vessel lumen, 
in Zen software to obtain vessel area calculated in μm2. Total HEV area was 
calculated as a proportion of the total tumor area. 
Immunofluorescence 
5 μm sections of frozen tissue embedded in OCT (RA Lamb) were fixed in 
ice-cold acetone or, in the case of CCL21 staining, in periodate-lysine-
paraformaldehyde fixative (PLP; 0.075 M lysine, 0.37 M sodium phosphate pH 7.2, 
1% formaldehyde, and 0.01 M NaIO4). Endogenous biotin was blocked with 
Avidin/Biotin blocking kit (VectorLabs), and nonspecific binding was blocked with 
2.5% normal horse serum (VectorLabs). Sections were incubated in primary antibody 
overnight at 4°C, washed with PBS, incubated in secondary antibody, washed again, 
and then mounted in Vectashield mounting medium with DAPI (VectorLabs). 
Sections were imaged using a Zeiss LSM710 or LSM800 confocal microscope, and 
serial images were assembled in Adobe Photoshop. Antibodies are listed in 
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Supplementary Table S1. T cells in stained, frozen tumors were counted per high 
power field of view, and an average of 10 fields of view was calculated per section. 
Gene expression analysis 
Data previously generated by MouseRef-8v2.0 whole genome expression bead 
chip (Illumina) profiling were reanalyzed for statistically significant differences 
between Treg+, Treg–  HEVlo and Treg- HEVhi groups (6). Briefly, RNA was extracted 
from OCT embedded tissue using TRIzol reagent (Invitrogen). RNA integrity was 
assessed on the Agilent 2100 Bioanalyzer, and samples with an RNA integrity 
number of 9 or more were used for gene expression profiling using MouseRef-8v2.0 
whole genome expression bead chip arrays and scanned on the iScan system 
(Illumina) as recommended by the manufacturer. Probe intensity values were 
corrected by background subtraction using Genome Studio software and subsequently 
log-2 and baseline (median) transformed using Genespring software (Agilent) before 
analysis of genes. Heat maps were generated using GENE-E software 
(https://software.broadinstitute.org/GENE-E/index.html). 
Statistical analyses 
The statistical relationships (correlations) between sets of measured variables 
were tested using the non-parametric Spearman’s correlation coefficient. The 
statistical difference between group(s) was determined by the non-parametric Mann 
Whitney t test or one-way ANOVA with Tukey’s post test to compare pairs of means. 
A P≤0.05 was considered significant. All statistical analyses were performed using 
GraphPad Prism software (GraphPad Prism Software, La Jolla, CA, USA).  
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Results 
Treg depletion disrupts LN HEV networks and induces intratumoral HEVs  
 We examined the impact of Treg depletion on LN architecture, focusing on 
HEV networks. Significant disruption was observed following loss of Tregs (Fig. 1A 
and B). Demarcation between B-cell and T-cell zones was diminished, and T cells and 
HEVs could be found throughout the swollen LN (Fig. 1B). Despite preserved PNAd 
expression, HEV morphology was significantly altered with vessels displaying more 
open lumen relative to HEVs of Treg-replete mice (Fig. 1E and F). These data 
indicate large-scale disorganization and disruption to function of the HEV network. 
Expression of the lymphoid chemokine CCL21 was restricted to HEVs in Treg-
replete LNs but upregulated in Treg-depleted LNs (Fig. 1I and J). 
HEVs have been documented in multiple human malignancies, where their 
presence is detected by immunohistochemical staining for PNAd (19,20). It remains 
unknown whether tumor HEVs share other similarities with canonical LN HEVs. In 
LNs, HEVs are situated within T-cell zones and cortical ridges, which mark the 
regions between B-cell and T-cell zones (Fig. 1A) (21). In contrast, tumor HEVs, 
which only developed in the absence of Tregs, displayed no apparent pattern of 
distribution within the tumor mass (Fig. 1C and D). Although often observed in close 
proximity to lymphocytes, HEVs were not embedded within discrete lymphoid 
follicles (Fig. 1D). Endothelial cells lining LN HEVs co-expressed PNAd and CD31 
and had a characteristic cuboidal morphology (Fig. 1E) (22,23). Expression of PNAd 
and CD31 did not entirely colocalize on LN HEVs, suggesting distinct patterns of 
expression at a cellular level. Although tumor HEVs also co-expressed PNAd and 
CD31, they lacked the distinctive plump morphology of LN HEV endothelial cells 
(Fig. 1G and H). In contrast to LN HEVs, CD31 and PNAd expression colocalized in 
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closer proximity on tumor HEVs. However, the flat endothelium that lines tumor 
HEVs is likely to hide subtle differences in cellular expression. Tumor HEVs also co-
expressed the adhesion molecule MAdCAM-1 (Supplementary Fig. S1). MAdCAM-1 
is normally expressed by endothelial cells in all LN HEVs early in development, and 
then it is rapidly downregulated in peripheral LNs but not mucosal LNs where HEVs 
maintain MAdCAM-1 and PNAd expression (24,25). This observation indicates that 
tumor HEVs are newly formed vessels in the tumor microenvironment. In contrast to 
LN HEVs, tumor HEVs did not express CCL21. Instead, expression of this 
chemokine colocalized with lymphatic vessel endothelial hyaluronan receptor 
(LYVE)-1 expression in the tumor, suggesting restriction to lymphatic vasculature, 
which was the case for Treg-replete tumors (Fig. 1K and L). These findings indicate a 
phenotype which contrasts with previously described reports of intratumoral HEVs 
(26-28). 
  As described previously, HEV+ tumors from Treg-depleted mice contain 
significantly increased numbers of CD8+ T cells and display significantly reduced 
growth rates relative to HEV– tumors (6). As shown in Fig. 2, HEV area, calculated as 
a percentage of total tumor area following quantification of PNAd+ vessels (Fig. 2A), 
fitted a bifurcated pattern of distribution (Fig. 2B). Using a threshold defined by 
median HEV area, we delineated tumors into HEVhi and HEVlo categories (Fig. 2B). 
Because HEVs also co-expressed MAdCAM-1, HEVhi and HEVlo tumors also 
showed ‘high’ and ‘low’ MAdCAM-1 expression, respectively, for both quantity of 
MAdCAM-1+ vessels and intensity of MAdCAM-1 staining (Supplementary Fig. S1). 
However, PNAd positivity was used to quantify tumor HEVs because MAdCAM-1 
can be expressed on other blood vessels and stromal cells (29). Although PNAd 
expression and not MAdCAM-1 defines the change in blood vessel phenotype and 
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function after Treg depletion, MAdCAM-1, present on some blood vessels in Treg 
replete tumors, may be needed for predisposing vessels to upregulate PNAd upon 
depletion of Tregs. Following Treg depletion, PNAd+ HEV quantity significantly 
correlated with both the extent of T-cell infiltration and the degree of tumor control, 
which were themselves also linked (Fig. 2C, E, and F). Profiling data previously 
generated for Treg-replete tumors, Treg-depleted HEVhi tumors, and Treg-depleted 
HEVlo tumors (6) were reanalyzed and revealed that HEVhi and HEVlo tumors were 
distinguished by a genetic signature indicative of a Type 1 Helper T-cell / Cytotoxic 
T-cell (CTL) response (Fig. 2D). As a result of this refinement, tumors were 
categorized as HEVhi or HEVlo in all subsequent experiments. 
CD11c+ dendritic cells are not essential for HEV neogenesis in tumors 
Evidence points to a role for CD11c+ DCs in the maintenance of LN HEVs 
(30), and DC abundance correlates positively with density of HEVs in human breast 
tumors (31,32). Considering that Treg depletion in Foxp3DTR mice increases the 
number and activation of DCs (10) and that DCs are observed in HEV-containing 
tumors (Fig. 3A), we tested whether DCs dictated HEV neogenesis in tumors by 
concurrently depleting CD11c+ DCs and Tregs in CD11c.DOG-Foxp3DTR mice. 
PNAd+ HEVs were detectable in tumors of DC-depleted mice (Fig. 3B), indicating 
that neogenesis of HEVs in tumors can proceed in the absence of DCs (Fig. 3C). 
However, we observed a trend towards fewer TILs and increased tumor growth rate 
relative to Treg– HEVhi DC-replete mice (Fig. 3D and E). Collectively, these data 
imply that although HEV development is not DC-dependent, the extent to which 
HEVs form, as well as impact on TIL frequencies and tumor growth, is compromised 
in the absence of DCs. It is possible that the effect of DCs on tumor growth is indirect 
through the driving of local activation and expansion of tumor-specific T cells. 
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T lymphocytes are essential for intratumoral neogenesis of HEVs 
Given that Treg depletion results in a significant increase in number, 
proliferation, and activation of intratumoral T cells, particularly in HEV-containing 
tumors (6,10), we postulated that T cells influence intratumoral HEV neogenesis. To 
examine this, Treg-depleted tumor-bearing mice were injected with anti-CD4 and 
anti-CD8 (33-35). Treg-depleted mice treated simultaneously with anti-CD4 and anti-
CD8 exhibited a significant reduction in tumor growth control (Fig. 4A). Almost all 
tumors recovered from these mice contained no HEVs. Remaining vessels had weaker 
PNAd+ staining (Fig. 4B and C), and a significant decrease in HEV area (Fig. 4F) 
relative to Treg-depleted tumors was seen. The most profound effect was observed 
upon CD8+ T cell–depletion (Fig. 4B-F). Considering T cell–depletion was 
suboptimal in Treg-depleted mice (Supplementary Fig. S2), these data show that a 
partial reduction in T-cell number, particularly CD8+ T cells, severely abrogates HEV 
neogenesis.  
HEV neogenesis in tumors relies on TNFR but not LTβR signaling 
To identify the molecular mechanisms underpinning HEV neogenesis in Treg-
depleted tumors, we focused our attention on LTβR and TNFR signaling pathways 
based on their involvement in LN development (8,30,36-38). LTβR.Fc (binds mouse 
LTαβ and LIGHT) and TNFRII.Ig (Etanercept; binds mouse TNF and LTα) were 
used to block the LTβR and TNFR signaling pathways, respectively (39). In-line with 
reports of wildtype animals, LTβR.Fc treatment of Treg-depleted mice resulted in loss 
of marginal zone (MZ) B cells, follicular dendritic cells (FDC), and MAdCAM-1 
expression on marginal sinus–lining stromal cells, confirming blockade of the LTβR 
signaling pathway (Supplementary Fig. S3 and S4) (14,40-43). Similarly, treatment of 
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Treg-depleted mice with TNFRII.Ig decreased splenic FDCs and MAdCAM-1 
expression, in-line with reports of wildtype animals (Supplementary Fig. S4) (44,45). 
Disruption of LN HEV morphology was observed in Treg-depleted mice 
receiving either LTβR.Fc or TNFRII.Ig, with vessels appearing larger, often with 
more open lumen (Supplementary Fig. S5). PNAd+ HEV were readily detected in 
tumors of LTβR.Fc-treated mice, and quantification revealed a significant increase in 
HEV area relative to Treg-depleted controls (Fig. 5A, B, and F). In contrast, HEVs in 
tumors of mice receiving TNFRII.Ig were fewer in number (Fig. 5C), and 
quantification revealed a profound reduction in total HEV area compared to controls 
(Fig. 5F). Administration of monoclonal antibodies specific for either of the two 
ligands for TNFRII, TNF and LTα, to tumor-bearing mice concurrently with Treg 
depletion also resulted in a decrease in HEV area relative to Treg-depleted controls 
(Fig. 5D-F). In-line with published literature, LTβR.Fc treatment did not influence 
MAdCAM-1 expression, and both PNAd and MAdCAM-1 were detected on tumor 
HEVs following LTβR.Fc treatment. Blockade of TNFR signaling with TNFRII.Ig, 
anti-TNF, or anti-LTα treatment reduced both PNAd and MAdCAM-1 expression in 
tumors, with any remaining vessels maintaining expression of both markers 
(Supplementary Fig. S6). Although the LTD-specific antibody blocks soluble LTD3 
and depletes cells expressing membrane bound LT (14), the effect of diminishing 
HEVs was not simply due to global T cell–depletion in this system. Overall, these 
data indicate that TNFR signaling, and not signaling via LTβR, drives intratumoral 
HEV neogenesis after Treg depletion. 
The increase in HEV area following LTβR.Fc treatment led to a significant 
increase in the number of TILs, whereas the decrease in HEV area observed after 
blockade of TNFR signaling resulted in no change in TIL frequency relative to Treg– 
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HEVlo controls (Fig. 5G). When normalized for HEV area, these changes were more 
pronounced, suggesting a difference in HEV function following these treatments (Fig. 
5H). Although administration of an agonist LTβR antibody to Treg-replete Foxp3DTR 
mice induced PNAd+ vessel formation in tumors, their presence was not accompanied 
by increased T-cell infiltration or reduced tumor growth relative to Treg+ controls 
(Supplementary Fig. S7). These data demonstrate that TNFR signaling is critical for 
development of functional HEV in tumors and indicate that blocking HEV 
development reduces the number of TILs and ability to control tumor growth. 
HEV area and tumor growth correlate with TNF+ tumor-infiltrating T cells  
Given our data, it seems likely that cytokines produced by T cells drive HEV 
development via TNFR signaling. To address this, proportions of CD8+ T cells in 
tumors and lymphoid organs expressing intracellular TNF were correlated with HEV 
area in tumors. A significant positive correlation was found between the proportion of 
intratumoral (but not LN-derived or splenic) CD8+ T cells producing TNF and 
intratumoral HEV area (Fig. 6A). These data directly index intratumoral HEV to TNF 
production by CD8+ TILs and support the premise that TNF-producing T cells are key 
drivers of HEV neogenesis in tumors. Additionally, proportion of TNF-producing 
CD8+ T cells also correlated with tumor growth rates (Fig. 6B). Although we could 
not distinguish between LTα3 and surface-bound LTαβ using anti-LTα, we found that 
T cells isolated from Treg-depleted tumors express LTα in addition to TNF at the 
mRNA level (Supplementary Fig. S8), consistent with the possibility that these TNF-
producing T cells also produce LTα. Overall, the data are indicative of a pathway 
where Treg depletion leads to activation of T cells, which then produce TNF/LTD3. 
This, in turn, promotes blood vessel differentiation into HEVs, resulting in superior T-
cell infiltration and tumor control (Fig. 6C).  
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Discussion 
In the presence of Tregs, T cells entering carcinogen-induced tumors express 
multiple and overlapping inflammatory chemokine receptor pairs to guide their 
migration to tumors (46). T cells also enter via aberrantly formed blood and lymphatic 
vessels (47). It is thought that Tregs become enriched within the TIL pool through 
selective proliferation and retention within the tumor microenvironment (48). In the 
absence of Tregs, a new route of entry presents itself in the form of intratumoral 
HEVs, which are significantly associated with TIL frequency and control of tumor 
growth (6). These vessels are morphologically distinct from those found in LNs and 
those reported previously in Treg-replete tumors arising either in the presence of 
strong antigenic stimulation (26) or as a result of administration of agonist LTER 
antibodies (this study). Thus, in the case of the fibrosarcomas described herein, Treg 
depletion is the defining event in development of intratumoral HEVs and the 
consequent favorable antitumor immune response, as PNAd+ vessels are not observed 
in Treg-replete tumors.  
The mechanisms identified herein as controlling intratumoral HEV neogenesis 
following Treg depletion are distinct from those occurring during ontogenic LN HEV 
development. Initial formation of HEV structure and abluminal PNAd expression on 
high endothelial cells in LNs proceeds in the absence of T or B cells (49), although 
the process of intratumoral HEV development is clearly T cell–dependent. A second 
departure from ontogenic HEV development is the reliance on TNFR signaling and 
dispensability of signaling via LTβR, strictly required for HEV formation and 
maintenance in LNs (8,36,37).  
We also observed fundamental differences in our findings compared to those 
reported in a study of tumors induced by OVA-expressing cancer cell lines (26). First, 
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although HEVs were readily observed in Treg-depleted carcinogen-induced tumors 
with clear implications for control of tumor growth, tyramide amplification was 
required to observe PNAd expression in cell line models, and its contribution to 
control of tumor growth was unclear. Second, in contrast to our findings, TNF played 
no role in HEV development in cell line–induced tumors, but a requirement for IFNγ-
induced expression of CCL21 on high endothelial cells was reported (26). In the Treg-
depleted tumors described herein, CCL21 expression is restricted to lymphatic 
vessels, indicating that it is not required for transmigration via HEVs. It has been 
suggested that CCL21+ lymphatic vessels may contribute to establishment of a 
memory response by enabling CCR7+ T cells to leave via the tumor lymphatics for re-
entry into draining LNs (50), and our previous observation that CCL21 is significantly 
upregulated in whole HEV-containing Treg-depleted tumors (6) supports this. 
Finally, we saw no evidence of organized lymphoid structures in HEV-
containing Treg-depleted carcinogen-induced tumors, whereas organized aggregates 
comprising of B cells and gp38 fibroblasts were observed in cell line–induced tumors 
(26). The presence of such tertiary lymphoid structures (TLS) containing HEVs in 
murine tumors has been associated with immunosuppression rather than immune 
activation (28,51) unless Tregs are depleted (27).  Therefore, expression of a strong 
neoantigen, such as OVA, resulting in activation of endogenous T cells or adoptively 
transferred transgenic T cells may allow immunosuppressive effects of TLS to be 
overcome. Such considerations might explain why evidence for a beneficial role of 
TLS/HEVs in human tumors is mixed, with some studies showing an association with 
a good prognosis whereas an increasing number of studies suggest a link to disease 
progression (19,20,52).  
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Models where tumors develop in vivo better represent the structural 
complexity of solid tumors with respect to the composition of the stroma, the myriad 
of cell-to-cell interactions occurring within, and tumor immunogenicity.  Tumor cell 
lines already possess the mutational and epigenetic changes required to rapidly 
become palpable tumors, but injection of carcinogens can allow for evolving 
interactions between the immune system and cancer cells during the process of 
transformation. Sustained interactions between the immune system and tumor cells 
during this early phase leads to a gradual reduction in tumor immunogenicity (9). 
Effector lymphocyte–driven development of LN-like vasculature in tumors, which 
then promotes antitumor immunity, may only occur when antigen stimulation is 
sufficient to overcome local immunosuppression. Depleting Tregs can significantly 
reverse this immunosuppression, lowering the threshold for immune activation and 
enabling HEV development to occur in response to immune-edited tumors.  
We observed that around 50% of tumors developed HEVs after Treg 
depletion. Depleting Tregs induced robust T-cell activation in all animals, indicating 
that although activation of these immune cell subsets is essential for HEV 
development, it is not sufficient to ensure that this occurs in all tumors. All tumors 
from Treg-replete mice contained some T cells. The range was small, and a similar 
proportion of these T cells produced TNF, indicating that the extent to which TNF-
producing T cells infiltrate the tumor pre-DT treatment is not a determining factor in 
whether the tumors go on to develop HEVs post-treatment. Significant differences in 
T-cell numbers and in the proportion of T cells producing TNF were only observed 
after treatment, correlating with HEVs. Our studies have demonstrated the inability of 
activated T cells, purified from Treg-depleted tumor-bearing animals, to induce HEV 
development in tumors of Treg-replete mice upon adoptive transfer. These data also 
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point to a yet unknown factor that renders tumors permissive to HEV neogenesis after 
Treg depletion. This may be a nonimmune component of the tumor microenvironment 
such as the endothelium, the extracellular matrix, or stromal components. Thus, future 
work should focus on defining key features that render some tumors refractive to 
HEV development after Treg depletion. Defining bottlenecks to HEV development in 
tumors may improve the design of new therapeutic approaches, combining 
immunotherapies targeting Tregs with regimens designed to alter tumor vasculature.  
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Figure Legends 
 
Figure 1: Treg depletion causes widespread disruption to LN HEV networks and induces 
intratumoral HEVs with a unique phenotype. 
(A-D) Representative images of HEVs (PNAd+; red), T cells (CD3+; blue), and B cells (CD45R+; 
green) in LNs and tumors of Foxp3DTR animals. (A) Treg+ and (B) Treg– LNs; (C) Treg+ and (D) 
Treg– tumors. (E-H) High power representative images of HEVs (PNAd+; red) dual-stained for 
CD31 (green) in LNs and tumors of Foxp3DTR animals. (E) Treg+ and (F) Treg– LNs; (G and H) 
Treg– tumors. (I-L) High power representative images of LNs and tumors of Foxp3DTR animals 
stained for CCL21 (red), HEVs (PNAd+; green), and LYVE-1 (blue). (I) Treg+ and (J) Treg– LNs; 
(K) Treg+ and (L) Treg– tumors. Merged images include the nuclear stain DAPI (blue in E-H; grey 
in I-L). Scale bars represent 50 μm in A-D and 20 μm in E-L. 
 
Figure 2: HEV area correlates with increased T-cell infiltration and reduced growth rate in Treg-
depleted tumors. 
(A) Representative image of HEVs (PNAd+; brown) in paraffin embedded tumors. Counterstain: 
haematoxylin. (B) Total HEV area, as a percentage of total tumor area. Data are presented as 
individual data points (individual mice) plus median, which was used to define a cut-off. HEVlo 
(light grey); HEVhi (dark grey); borderline data points (open circles) were excluded thereafter. (C) 
Number of intratumoral CD8+ T cells plotted against total HEV area. (D) Transcriptional profiles 
revealed by microarray of Treg– HEVhi, Treg– HEVlo, and Treg+ HEV– tumors (n = 5 per group). 
Altered genes involved in Th1/CTL immune responses are displayed as a heat map of log2-fold 
change relative to the global median of genes. (E) Number of intratumoral CD8+ T cells plotted 
against tumor growth rates (k, days-1). (F) Total HEV area plotted against tumor growth rate (k, 
days-1). Statistical significance was determined by Spearman’s correlation coefficient test (r 
statistic and P values are shown). n = 19. 
 
Figure 3: CD11c+ dendritic cells are not essential for HEV neogenesis in tumors. 
(A) Representative image of HEVs (PNAd+; red) alongside MHC Class II+ (blue) and CD11c+ 
(green) DCs in a tumor of a Treg– Foxp3DTR animal. (B) Representative image of HEVs (PNAd+; 
brown) in tumor of a Treg– CD11c– CD11c.DOG-Foxp3DTR animal. Counterstain: haematoxylin. 
(C) Total HEV area of Treg– CD11c– mice compared to Treg– controls. Data are presented as 
individual data points (individual mice) plus median. Statistical significance was determined by 
Mann Whitney t tests. n = 8 Treg– CD11c– animals; n = 19 Treg– animals. (D) Number of CD8+ T 
cells in tumors of Treg– HEVlo (n = 15) Foxp3DTR animals, Treg– HEVhi (n = 16) Foxp3DTR 
animals, and Treg– CD11c– CD11c.DOG-Foxp3DTR animals (n = 9). (E) Tumor growth rates (k, 
days-1) for Treg– HEVlo (n = 15) Foxp3DTR animals, Treg– HEVhi (n = 15) Foxp3DTR animals, and 
Treg– CD11c– CD11c.DOG-Foxp3DTR animals (n = 8). Statistical significance was determined by 
one-way ANOVA with Tukey’s test to compare pairs of means (* = P≤0.05, ** = P≤0.01, *** = 
P≤0.001). 
 
Figure 4: Depletion of T cells, in particular CD8+ T cells, significantly abrogates HEV neogenesis 
in tumors. 
(A) Tumor growth rates (k, days-1) for Treg– HEVlo (n = 15), Treg– HEVhi (n = 15), and Treg– 
CD4–/CD8– (n = 16) Foxp3DTR animals. Statistical significance was determined by one-way 
ANOVA with Tukey’s test to compare pairs of means (** = P≤0.01, **** = P≤0.0001). (B-E) 
Representative images of HEVs (PNAd+; brown) in tumors of (B) Treg–, (C) Treg– CD4–/CD8–, 
(D) Treg– CD4–, and (E) Treg– CD8– Foxp3DTR mice. Counterstain: haematoxylin. (F) Total HEV 
area of Treg– CD4–/CD8– (n = 16), Treg– CD4– (n = 11), and Treg– CD8– (n = 8) animals 
compared to Treg– controls (n = 19). Data are presented as individual data points (individual mice) 
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plus median. Statistical significance was determined by Mann Whitney t tests; P values are shown 
for each group compared to Treg– controls.  
 
Figure 5: Blockade of TNFR signaling, but not LymphotoxinβR signaling, severely abrogates 
HEV neogenesis in tumors. 
(A-D) Representative images of HEVs (PNAd+; brown) in tumors from Foxp3DTR animals. (A) 
Treg–; (B) Treg– plus LTβR.Fc; (C) Treg– plus TNFRII.Ig; (D) Treg– plus anti-TNF; and (E) Treg– 
plus anti-LTα. Counterstain: haematoxylin. (F) Total HEV area of tumors from mice treated with 
LTβR.Fc, TNRFII.Ig, anti-TNF, or anti-LTα compared to Treg– controls. Data are presented as 
individual data points (individual mice) plus median. n = 19 Treg– animals; n = 13 Treg– plus LT
șR.Fc animals; n = 17 Treg– plus TNFRII.Ig animals; n = 11 Treg– plus anti-TNF; n = 8 Treg- 
plus anti-LTα. (G) Number of CD8+ T cells in tumors of Treg– HEVlo (n = 15), Treg– HEVhi (n = 
16), Treg– plus LTβR.Fc (n = 13), and Treg– plus TNFRII.Ig (n = 17) Foxp3DTR animals. 
Statistical significance was determined by one-way ANOVA with Tukey’s test to compare pairs 
of means (* = P≤0.05, ** = P≤0.01, *** = P≤0.001). (H) Data as for (G) but normalized for total 
HEV area. 
 
Figure 6: HEV area and tumor growth rates correlate with the proportions of TNF+ tumor-
infiltrating T cells.  
(A) Correlations between total HEV area within the tumor (%, y axis) and the proportion of CD8+ 
T cells expressing intracellular TNF in spleen, non-tumor draining lymph nodes (NDLNs), tumor 
draining lymph nodes (DLNs), or tumor as indicated (x axis). Statistical significance was 
determined by Spearman’s correlation coefficient test (r statistic and P values are shown). n = 9. 
(B) Correlation between tumor growth rate (k, days-1) and the proportion of CD8+ T cells 
expressing intracellular TNF in tumors. Statistical significance was determined by Spearman’s 
correlation coefficient test (r statistic and P values are shown). n = 9. (C) Schematic summary of 
the mechanism presented herein. 
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